Market Overview

UPDATE: Aegis Capital Downgrades SciClone Pharmaceuticals to Hold on Financial Restatement Due to NovaMed Accounting Errors

Related SCLN
33 Stocks Moving In Thursday's Mid-Day Session
Wall Street's M&A Chatter From June 8: Cabelas, SciClone Pharma, Microsoft-Hexadite, Athenahealth-Praxify

In a report published Monday, Aegis Capital downgraded its rating on SciClone Pharmaceuticals (NASDAQ: SCLN) from Buy to Hold.

Aegis Capital noted, “SciClone recently announced that it will restate the financial statements for Q2-Q3 of 2011 and Q1-Q3 of 2012 due to accounting errors in its China subsidiary NovaMed. According to the firm, this will likely increase 9-month 2012 revenue by ~$3mm and before-tax income by ~$2mm, as well as decrease FY2011 revenue by ~$1mm and before-tax income by <$1mm. The issue primarily pertains to the timing of Pfizer products revenue recognition within NovaMed, which was effectively a “sell-through” method as opposed to the “sell-in” method originally drafted with the distributor. The Pfizer products had combined revenue of ~$9mm for FY2011 and 9-month 2012. The accounting issue also pertains to recognition of product return reserves for Aggrastat, another product sold by NovaMed. Aggrastat had combined revenue of ~$3.6mm for FY2011 and 9-month 2012. The restatement is slated to be presented with the coming 10-K. On a separate note, SciClone's auditor Ernst & Young decided not to stand for re-appointment after the restatement and 2012 10-K. In the wake of this news and the uncertainty the firm faces in securing another prestigious public accounting firm to act as auditor, we are downgrading our rating to Hold without a price target on SCLN shares.”

SciClone Pharmaceuticals closed on Friday at $4.82.

Latest Ratings for SCLN

Nov 2016Maxim GroupInitiates Coverage OnBuy
Jun 2015MLV & Co.Initiates Coverage onBuy
Nov 2014BWS FinancialDowngradesBuyHold

View More Analyst Ratings for SCLN
View the Latest Analyst Ratings

Posted-In: Aegis CapitalAnalyst Color Downgrades Analyst Ratings


Related Articles (SCLN)

View Comments and Join the Discussion!